Pharmacogenomics Journal

Aims & Scope

The Pharmacogenomics Journal is a print and electronic journal, which is dedicated to the rapid publication of original research on pharmacogenomics and its clinical applications.

Key areas of coverage include: Personalized medicine Effects of genetic variability on drug toxicity and efficacy Identification and functional characterization of polymorphisms relevant to drug action Pharmacodynamic and pharmacokinetic variations and drug efficacy Integration of new developments in the genome project and proteomics into clinical medicine, pharmacology, and therapeutics Clinical applications of genomic science Identification of novel genomic targets for drug development Potential benefits of pharmacogenomics.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.9
2024	2.90

SJR (SCImago Journal Rank)

Year	Value
2024	0.694

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	99

Journal Rank

Year	Value
2024	8196

Journal Citation Indicator

Year	Value
2024	367

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

  Citation: 848

  Authors: M

• UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

  Citation: 566

  Authors: L, S, L, M, J, T, G F, E E, R L, M J

• Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease

  Citation: 518

  Authors: M E, A M, J F B, G C, S, I M, M E, D A, A D

• Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

  Citation: 430

  Authors: S T, J, V, Y-P, S A, A, R, D, S, H-J

• Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

  Citation: 387

  Authors: D, Y, S A, G E, W

• HIBAG—HLA genotype imputation with attribute bagging

  Citation: 366

  Authors: X, J, C, J C, M G, M R, B S

• Common VKORC1 and GGCX polymorphisms associated with warfarin dose

  Citation: 366

  Authors: M, L Y, K, J, S, N, O, H, C, D, P

• Pharmacogenomics of human UDP-glucuronosyltransferase enzymes

  Citation: 343

  Authors: C

• Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication

  Citation: 341

  Authors: J, H, M, J-Tha, J, I, J

• The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression

  Citation: 336

  Authors: S, S, N, H, N, S

---